Cytomed TherapeuticsGDTC
13F holders, Q2 2025 (June 30)2holders
0new positions
0sold out
1famous investor
$2.18avg. 13F price*
At the end of Q2 2025, 2 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Citadel Advisors ($59K) and UBS Group AG ($40K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 13,553 shares bought, net +13,553 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Citadel Advisors | 0.00% | Add +60.4% | 27,669 | $59K |
| UBS Group AG | 0.00% | Add +21.7% | 17,581 | $40K |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.